The changing role of radiation therapy in the management of oligometastatic disease
It is clear from surgical series that there are selected patients presenting with localised metastatic disease who can be cured by radical ablation of the metastasis. To date this has been limited to surgical resection but the evolution of stereotactic ablative body radiotherapy (SABR) has opened ne...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-03-01
|
| Series: | Technical Innovations & Patient Support in Radiation Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405632417300021 |
| Summary: | It is clear from surgical series that there are selected patients presenting with localised metastatic disease who can be cured by radical ablation of the metastasis. To date this has been limited to surgical resection but the evolution of stereotactic ablative body radiotherapy (SABR) has opened new opportunities. Hypofractionated radiation delivery in 1 to 5 fractions can achieve durable local control with low toxicity. The focus is now to develop robust biomarkers so that those with true oligometastatic and thereby potentially curable disease can be selected for this approach. Keywords: Oligometastases, Stereotactic ablative body radiotherapy (SABR), Biomarkers |
|---|---|
| ISSN: | 2405-6324 |